CSBio CSBio

X
[{"orgOrder":0,"company":"IAMA Therapeutics","sponsor":"Italian Institute of Technology","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IAMA Therapeutics Partners with the Italian Institute of Technology to Embark on Landmark Research on Neuroscience Drug Discovery","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Small molecule","productStatus":"Undisclosed","date":"March 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"IAMA Therapeutics"},{"orgOrder":0,"company":"Vitalunga","sponsor":"Hebrew University","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Startup Vitalunga Creates Novel Oral Drug to Enable Disease-free Aging; Pre-clinical Studies Expected to Begin in Near Future","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Vitalunga"},{"orgOrder":0,"company":"IRBM","sponsor":"Rainwater Charitable Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRBM, Rainwater Charitable Foundation and Weill Cornell Medicine Join Forces to Progress Therapies for Neurodegenerative Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery","country":"ITALY","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"IRBM"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The collaboration aims to identify small molecule cGAS (cyclic GMP-AMP synthase) inhibitors for the treatment of tauopathies and other neurodegenerative diseases.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Rainwater Charitable Foundation

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration July 12, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Hebrew University Portfolio Company addresses modern medicine’s number one problem: extending lifespan without disease and has the potential to improve quality of life for the world’s rapidly growing aging population.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Hebrew University

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 23, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the collaboration with the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), they will design and profile new classes of compounds targeting cation cotransporters in the CNS area.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Italian Institute of Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration March 29, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY